688278 特宝生物
交易中 11-19 10:11:41
资讯
新帖
简况
股市必读:特宝生物新发布《特宝生物:国金证券股份有限公司关于厦门特宝生物工程股份有限公司向不特定对象发行可转换公司债券2026年第一次临时受托管理事务报告》
证券之星 · 02:50
股市必读:特宝生物新发布《特宝生物:国金证券股份有限公司关于厦门特宝生物工程股份有限公司向不特定对象发行可转换公司债券2026年第一次临时受托管理事务报告》
特宝生物:11月16日召开业绩说明会,投资者参与
证券之星 · 11-17 19:01
特宝生物:11月16日召开业绩说明会,投资者参与
特宝生物(688278)披露2024年限制性股票激励计划归属结果暨股份上市公告,11月17日股价下跌0.53%
证券之星 · 11-17 17:52
特宝生物(688278)披露2024年限制性股票激励计划归属结果暨股份上市公告,11月17日股价下跌0.53%
股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》
证券之星 · 11-16
股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》
特宝生物(688278)11月12日主力资金净买入770.97万元
证券之星 · 11-13
特宝生物(688278)11月12日主力资金净买入770.97万元
股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》
证券之星 · 11-13
股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》
股市必读:特宝生物(688278)11月11日董秘有最新回复
证券之星 · 11-12
股市必读:特宝生物(688278)11月11日董秘有最新回复
特宝生物:设立伦理委员会监督研发伦理规范
证券之星 · 11-11
特宝生物:设立伦理委员会监督研发伦理规范
特宝生物(688278)11月9日主力资金净卖出188.76万元
证券之星 · 11-10
特宝生物(688278)11月9日主力资金净卖出188.76万元
股市必读:特宝生物新发布《特宝生物:关于召开2026年第三季度业绩说明会的公告》
证券之星 · 11-09
股市必读:特宝生物新发布《特宝生物:关于召开2026年第三季度业绩说明会的公告》
特宝生物单季利润近乎归零 应收存货双高暴露增长质量隐忧
新浪证券 · 11-06
特宝生物单季利润近乎归零 应收存货双高暴露增长质量隐忧
特宝生物(688278)披露召开2026年第三季度业绩说明会的公告,11月05日股价上涨1.35%
证券之星 · 11-05
特宝生物(688278)披露召开2026年第三季度业绩说明会的公告,11月05日股价上涨1.35%
股市必读:特宝生物新发布《特宝生物:关于对外捐赠的公告》
证券之星 · 11-04
股市必读:特宝生物新发布《特宝生物:关于对外捐赠的公告》
特宝生物(688278)披露关于股份回购进展公告,11月03日股价上涨1.59%
证券之星 · 11-03
特宝生物(688278)披露关于股份回购进展公告,11月03日股价上涨1.59%
特宝生物最新公告:拟捐赠不超过6万支益佩生及138.6万元现金支持公益项目
证券之星 · 11-02
特宝生物最新公告:拟捐赠不超过6万支益佩生及138.6万元现金支持公益项目
特宝生物(688278)10月28日主力资金净卖出2522.25万元
证券之星 · 10-29
特宝生物(688278)10月28日主力资金净卖出2522.25万元
10月28日特宝生物涨5.46%,华安聚恒精选混合A基金重仓该股
证券之星 · 10-28
10月28日特宝生物涨5.46%,华安聚恒精选混合A基金重仓该股
特宝生物涨5.46%,国金证券二个月前给出“买入”评级
证券之星 · 10-28
特宝生物涨5.46%,国金证券二个月前给出“买入”评级
特宝生物:将药品研发进入III期临床试验阶段前的所有研发支出予以费用化
证券之星 · 10-28
特宝生物:将药品研发进入III期临床试验阶段前的所有研发支出予以费用化
股市必读:特宝生物三季报 - 第三季度单季净利润同比下降99.65%
证券之星 · 10-26
股市必读:特宝生物三季报 - 第三季度单季净利润同比下降99.65%
加载更多
公司概况
公司名称:
厦门特宝生物工程股份有限公司
所属行业:
医药制造业
上市日期:
2020-01-17
主营业务:
厦门特宝生物工程股份有限公司的主营业务是免疫和代谢领域创新药物研发、生产和销售。公司的主要产品是派格宾、益佩生、珮金、特尔立、特尔津、特尔康。派格宾于2025年10月获批成为全球首个以慢乙肝临床治愈为治疗终点的药物,是该领域重要基石药物。
发行价格:
8.24
{"stockData":{"symbol":"688278","market":"SH","secType":"STK","nameCN":"特宝生物","latestPrice":41.9,"timestamp":1795054301000,"preClose":42.14,"halted":0,"volume":354532,"delay":0,"changeRate":-0.0057,"floatShares":409999999,"shares":409999999,"eps":2.0545,"marketStatus":"交易中","change":-0.24,"latestTime":"11-19 10:11:41","open":42,"high":42.5,"low":41.77,"amount":14925800,"amplitude":0.0173,"askPrice":41.88,"askSize":2,"bidPrice":41.81,"bidSize":8,"shortable":0,"etf":0,"ttmEps":2.0545,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1795059000000},"marketStatusCode":2,"adr":0,"adjPreClose":42.14,"symbolType":"stock_kcb","openAndCloseTimeList":[[1795051800000,1795059000000],[1795064400000,1795071600000]],"highLimit":46.35,"lowLimit":37.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410083158,"isCdr":false,"pbRate":5.55,"roa":"--","peRate":20.394257,"roe":"14.22%","epsLYR":2.53,"committee":0.172414,"marketValue":17182000000,"turnoverRate":0.0009,"status":1,"floatMarketCap":17182000000},"requestUrl":"/m/hq/s/688278","defaultTab":"news","newsList":[{"id":"2684915982","title":"股市必读:特宝生物新发布《特宝生物:国金证券股份有限公司关于厦门特宝生物工程股份有限公司向不特定对象发行可转换公司债券2026年第一次临时受托管理事务报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684915982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684915982?lang=zh_cn&edition=full","pubTime":"2026-11-19 02:50","pubTimestamp":1795027825,"startTime":"0","endTime":"0","summary":"公司公告汇总:因股本变动,“特宝转债”转股价格由58.56元/股调整为58.47元/股,自2026年11月17日起生效。公司公告汇总特宝生物:国金证券股份有限公司关于厦门特宝生物工程股份有限公司向不特定对象发行可转换公司债券2026年第一次临时受托管理事务报告厦门特宝生物工程股份有限公司因完成2024年限制性股票激励计划部分股份归属,公司股本由408,189,480股增至410,083,158股。本次调整不涉及暂停转股,不影响公司正常经营及偿债能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111900001763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600109","BK0201","BK0012","BK0239","688278","BK0028","BK0276","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684604156","title":"特宝生物:11月16日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2684604156","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684604156?lang=zh_cn&edition=full","pubTime":"2026-11-17 19:01","pubTimestamp":1794913308,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年11月17日特宝生物发布公告称公司于2026年11月16日召开业绩说明会。公司自主研发的核心产品派格宾是全球首个获批慢乙肝临床治愈相关适应症的基石药物,循证证据扎实;同时加速推进CT580、CT201、CT400、CT560等创新管线,研发投入按短、中、长期统筹资源配置。具体内容详见公司披露的ESG报告、定期报告等相关公告。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700035699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684069776","title":"特宝生物(688278)披露2024年限制性股票激励计划归属结果暨股份上市公告,11月17日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2684069776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684069776?lang=zh_cn&edition=full","pubTime":"2026-11-17 17:52","pubTimestamp":1794909159,"startTime":"0","endTime":"0","summary":"截至2026年11月17日收盘,特宝生物报收于42.9元,较前一交易日下跌0.53%,最新总市值为175.93亿元。公告显示,公司已完成2024年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记。本次归属新增股份1,893,678股,其中首次授予部分1,349,688股,预留授予部分543,990股,上市流通日为2026年11月19日。本次归属完成后,公司总股本由408,189,480股增至410,083,158股,未导致公司实际控制人变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700032094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683650282","title":"股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683650282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683650282?lang=zh_cn&edition=full","pubTime":"2026-11-16 05:16","pubTimestamp":1794777374,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总:11月13日游资资金净流入652.33万元,占总成交额8.76%。公司公告汇总:特宝生物发布可转债投资者适当性风险提示公告,明确“特宝转债”自2027年2月3日起可转股,参与转股须符合科创板股票投资者适当性管理要求。交易信息汇总资金流向11月13日主力资金净流入13.3万元,占总成交额0.18%;游资资金净流入652.33万元,占总成交额8.76%;散户资金净流出665.63万元,占总成交额8.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600001657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683490475","title":"特宝生物(688278)11月12日主力资金净买入770.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683490475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683490475?lang=zh_cn&edition=full","pubTime":"2026-11-13 08:20","pubTimestamp":1794529236,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月12日收盘,特宝生物报收于43.85元,上涨0.8%,换手率0.53%,成交量2.16万手,成交额9488.82万元。11月12日的资金流向数据方面,主力资金净流入770.97万元,占总成交额8.13%,游资资金净流出937.64万元,占总成交额9.88%,散户资金净流入166.67万元,占总成交额1.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300009081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683641519","title":"股市必读:特宝生物新发布《特宝生物:关于可转债投资者适当性要求的风险提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683641519","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683641519?lang=zh_cn&edition=full","pubTime":"2026-11-13 02:00","pubTimestamp":1794506439,"startTime":"0","endTime":"0","summary":"截至2026年11月12日收盘,特宝生物报收于43.85元,上涨0.8%,换手率0.53%,成交量2.16万手,成交额9488.82万元。当日关注点交易信息汇总:11月12日主力资金净流入770.97万元,占总成交额8.12%。公司公告汇总:特宝生物发布可转债投资者适当性风险提示公告,明确“特宝转债”自2027年2月3日起可转股,参与转股须符合科创板股票投资者适当性管理要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682817455","title":"股市必读:特宝生物(688278)11月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2682817455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682817455?lang=zh_cn&edition=full","pubTime":"2026-11-12 02:49","pubTimestamp":1794422950,"startTime":"0","endTime":"0","summary":"截至2026年11月11日收盘,特宝生物报收于43.5元,下跌1.41%,换手率0.57%,成交量2.32万手,成交额1.01亿元。董秘最新回复投资者: 董秘您好!关注到公司主营专科用制剂,ESG报告中披露了科技伦理治理架构与伦理审查制度。当日关注点交易信息汇总:11月11日主力资金净流入192.05万元,占总成交额1.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200002548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682374055","title":"特宝生物:设立伦理委员会监督研发伦理规范","url":"https://stock-news.laohu8.com/highlight/detail?id=2682374055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682374055?lang=zh_cn&edition=full","pubTime":"2026-11-11 16:57","pubTimestamp":1794387443,"startTime":"0","endTime":"0","summary":"关注到公司主营专科用制剂,ESG报告中披露了科技伦理治理架构与伦理审查制度。公司依据《GB/T35892-2018 实验动物福利伦理审查指南》,建立并持续优化《实验动物管理委员会章程及实验动物伦理委员会章程》《实验动物室人员及动物福利管理程序》及各项动物实验操作标准规程,设立伦理委员会,负责监督研发过程中的伦理规范,确保所有项目符合法规和公司政策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100034130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682135503","title":"特宝生物(688278)11月9日主力资金净卖出188.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682135503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682135503?lang=zh_cn&edition=full","pubTime":"2026-11-10 09:27","pubTimestamp":1794274024,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月9日收盘,特宝生物报收于43.82元,下跌2.82%,换手率0.44%,成交量1.79万手,成交额7968.58万元。11月9日的资金流向数据方面,主力资金净流出188.76万元,占总成交额2.37%,游资资金净流入151.37万元,占总成交额1.9%,散户资金净流入37.39万元,占总成交额0.47%。融券方面,融券卖出3400.0股,融券偿还898.0股,融券余量12.2万股,融券余额534.53万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000010670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682826113","title":"股市必读:特宝生物新发布《特宝生物:关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682826113","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682826113?lang=zh_cn&edition=full","pubTime":"2026-11-09 03:48","pubTimestamp":1794167294,"startTime":"0","endTime":"0","summary":"截至2026年11月6日收盘,特宝生物报收于45.09元,下跌1.57%,换手率0.49%,成交量2.0万手,成交额9048.41万元。公司公告汇总:特宝生物将于2026年11月16日召开2026年第三季度业绩说明会,参会高管包括董事长兼总经理孙黎、副总经理兼财务总监杨毅玲、董事会秘书曾弘霖及独立董事刘圻。投资者可于2026年11月9日至11月13日16:00前通过上证路演中心或公司邮箱提交问题。说明会后可通过上证路演中心查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900001076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681831278","title":"特宝生物单季利润近乎归零 应收存货双高暴露增长质量隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2681831278","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681831278?lang=zh_cn&edition=full","pubTime":"2026-11-06 14:03","pubTimestamp":1793944980,"startTime":"0","endTime":"0","summary":"特宝生物2026 年三季报的表现远超市场预期。前三季度公司营收同比增长 10.2%,但归母净利润同比下滑 28.34%,其中第三季度净利润仅 83.6 万元,同比大降 99.65%,近乎归零。除了研发投入与税率调整的短期冲击,公司持续高企的应收账款、不断拉长的存货周转周期,以及募资大额理财背后的资金效率问题,都暴露出其增长质量的深层隐忧。02应收存货双高增长质量存疑比短期利润波动更值得警惕的,是特宝生物持续恶化的营运效率。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-11-06/doc-inixuqhy8817684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681104074","title":"特宝生物(688278)披露召开2026年第三季度业绩说明会的公告,11月05日股价上涨1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681104074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681104074?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:40","pubTimestamp":1793889622,"startTime":"0","endTime":"0","summary":"截至2026年11月5日收盘,特宝生物报收于45.81元,较前一交易日上涨1.35%,最新总市值为186.99亿元。该股当日开盘45.04元,最高45.89元,最低44.76元,成交额达1.14亿元,换手率为0.61%。公告显示,公司将于2026年11月16日10:00-11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会,介绍公司经营成果和财务状况。投资者可于2026年11月9日至11月13日16:00前通过上证路演中心或公司邮箱提交问题。说明会后可通过上证路演中心查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500043288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680777820","title":"股市必读:特宝生物新发布《特宝生物:关于对外捐赠的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680777820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680777820?lang=zh_cn&edition=full","pubTime":"2026-11-04 05:04","pubTimestamp":1793739854,"startTime":"0","endTime":"0","summary":"公司公告汇总特宝生物:关于对外捐赠的公告厦门特宝生物工程股份有限公司于2026年11月2日召开第九届董事会第二十七次会议,审议通过《关于对外捐赠的议案》,决定向北京红心相通公益基金会捐赠不超过6万支益佩生及不超过138.60万元人民币现金,用于支持“益路相伴”患者援助项目。特宝生物:关于不向下修正“特宝转债”转股价格的公告截至2026年11月2日,厦门特宝生物工程股份有限公司股价已触发“特宝转债”转股价格向下修正条款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400006708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680740262","title":"特宝生物(688278)披露关于股份回购进展公告,11月03日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680740262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680740262?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:25","pubTimestamp":1793705133,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘,特宝生物报收于44.77元,较前一交易日上涨1.59%,最新总市值为182.75亿元。该股当日开盘43.81元,最高44.85元,最低43.37元,成交额达8998.48万元,换手率为0.5%。公司于近日披露《关于股份回购进展公告》。公告显示,厦门特宝生物工程股份有限公司于2026年5月11日召开董事会,审议通过以集中竞价交易方式回购股份的方案,回购期限为2026年5月12日至2027年5月11日,拟回购金额为30,000万元至50,000万元,用于员工持股计划或股权激励及转换可转债。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300037997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680513097","title":"特宝生物最新公告:拟捐赠不超过6万支益佩生及138.6万元现金支持公益项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2680513097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680513097?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:45","pubTimestamp":1793619954,"startTime":"0","endTime":"0","summary":"特宝生物(688278.SH)公告称,公司董事会审议通过对外捐赠议案,决定向北京红心相通公益基金会捐赠不超过6万支益佩生(怡培生长激素注射液)及不超过138.60万元现金,用于支持“益路相伴”患者援助项目。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200030493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403446","title":"特宝生物(688278)10月28日主力资金净卖出2522.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679403446?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:43","pubTimestamp":1793234597,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月28日收盘,特宝生物报收于44.22元,上涨5.46%,换手率1.08%,成交量4.41万手,成交额1.93亿元。10月28日的资金流向数据方面,主力资金净流出2522.25万元,占总成交额13.04%,游资资金净流出1072.9万元,占总成交额5.55%,散户资金净流入3595.15万元,占总成交额18.59%。融券方面,融券卖出4671.0股,融券偿还5748.0股,融券余量11.81万股,融券余额522.46万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678451957","title":"10月28日特宝生物涨5.46%,华安聚恒精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678451957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678451957?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:42","pubTimestamp":1793176929,"startTime":"0","endTime":"0","summary":"证券之星消息,10月28日特宝生物涨5.46%,收盘报44.22元,换手率1.08%,成交量4.41万手,成交额1.93亿元。重仓特宝生物的公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级6家。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为华安基金的华安聚恒精选混合A。华安聚恒精选混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800036566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678923451","title":"特宝生物涨5.46%,国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678923451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678923451?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:41","pubTimestamp":1793176917,"startTime":"0","endTime":"0","summary":"今日特宝生物涨5.46%,收盘报44.22元。2026年8月19日,国金证券研究员甘坛焕,马居东发布了对特宝生物的研报《益佩生商业化提速,二季度利润实现高增长》,该研报对特宝生物给出“买入”评级。维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国金证券的甘坛焕、马居东。特宝生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800036560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678455508","title":"特宝生物:将药品研发进入III期临床试验阶段前的所有研发支出予以费用化","url":"https://stock-news.laohu8.com/highlight/detail?id=2678455508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678455508?lang=zh_cn&edition=full","pubTime":"2026-10-28 15:33","pubTimestamp":1793172811,"startTime":"0","endTime":"0","summary":"26年3季度当期利润大幅下降,是BD支出计入了当期的费用。公司严格按照企业会计准则及公司研发支出资本化政策规定,对相关款项进行会计处理:将药品研发进入III期临床试验阶段前的所有研发支出予以费用化;将药品研发进入III期临床试验阶段的时点作为资本化开始的时点,将可直接归属的研发支出予以资本化。授权引进项目尚未进入III期临床试验阶段,其相关支出予以费用化处理。销售里程碑款及特许权使用费在实际发生时计入当期损益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800029872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136702","title":"股市必读:特宝生物三季报 - 第三季度单季净利润同比下降99.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136702?lang=zh_cn&edition=full","pubTime":"2026-10-26 03:38","pubTimestamp":1792957089,"startTime":"0","endTime":"0","summary":"2026年第三季度单季度主营收入8.96亿元,同比下降7.55%;归母净利润83.6万元,同比下降99.65%;扣非净利润2254.71万元,同比下降90.67%;负债率46.65%,毛利率88.34%,财务费用600.25万元,投资收益269.83万元。公司公告汇总特宝生物:2026年第三季度报告2026年第三季度营业收入8.96亿元,同比下降7.55%;归母净利润83.6万元,同比下降99.65%。年初至报告期末营业收入27.32亿元,同比增长10.20%;归母净利润4.77亿元,同比下降28.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795054310068,"stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.1045},{"period":"3month","weight":-0.3516},{"period":"6month","weight":-0.2592},{"period":"1year","weight":-0.4472},{"period":"ytd","weight":-0.4908}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0384},{"period":"3month","weight":-0.0809},{"period":"6month","weight":-0.1277},{"period":"1year","weight":-0.0893},{"period":"ytd","weight":-0.096}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"厦门特宝生物工程股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11842人(较上一季度增加12.09%)","perCapita":"34629股","listingDate":"2020-01-17","address":"福建省厦门市海沧区新阳工业区翁角路330号","registeredCapital":"41008万元","survey":" 厦门特宝生物工程股份有限公司的主营业务是免疫和代谢领域创新药物研发、生产和销售。公司的主要产品是派格宾、益佩生、珮金、特尔立、特尔津、特尔康。派格宾于2025年10月获批成为全球首个以慢乙肝临床治愈为治疗终点的药物,是该领域重要基石药物。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"特宝生物(688278)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供特宝生物(688278)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"特宝生物,688278,特宝生物股票,特宝生物股票老虎,特宝生物股票老虎国际,特宝生物行情,特宝生物股票行情,特宝生物股价,特宝生物股市,特宝生物股票价格,特宝生物股票交易,特宝生物股票购买,特宝生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"特宝生物(688278)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供特宝生物(688278)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}